Provided herein are methods for selecting a treatment for a subject that include (i) determining a level of soluble ST2 in a first biological sample from a subject obtained from the subject at a first time, (ii) determining a level of soluble ST2 in a second biological sample obtained from the subject at a second time point (iii) comparing the level of soluble ST2 in the first biological sample to the level of soluble ST2 in the second biological sample (iv) identifying a subject having an elevated level of soluble ST2 in the second biological sample compared to the level of soluble ST2 in the first biological sample as having an increased risk of a VTA (ventricular tachyarrhythmia) event and (v) selected an implanted cardiac defibrillator (ICD), a cardiac resynchronization therapy (CRT) device, or a combination ICD-CRT (CRT-D) device for the subject identified as having an increased risk of a VTA event. Also provided are methods for evaluating the risk of a VTA event in a subject.
METHODS FOR TREATING OR PREDICTING RISK OF VENTRICULAR TACHYARRHYTHMIA EVENT